Photo of Massimo Serra, Biologist
Massimo Serra, Biologist
+39-051-6366762
+39-051-6366761
  1. Campanacci M., Bagnara G.P., Serra M., Giovannini M., Tomasi P., Pileri S., Poggi S., Lollini P.-L., Picci P., Paolucci G. Giant cell tumor of bone: a model for the in vitro human osteoclast characterization. Tumori 75:389-395, 1989.
  2. Bagnara G.P., Serra M., Giovannini M., Badiali M., Stella M., Montaldi A., Granchi D., Paolucci P., Rocchi P., Pession A., Picci P., Paolucci G., Campanacci M., Tessarollo L., Cavazzana A. Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAP-35). International Journal of Cell Cloning 8:409-424, 1990.
  3. Baldini N., Scotlandi K., Serra M., Kusuzaki K., Shikita T., Manara M.C., Maurici D., Campanacci M. Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. J Cancer Res Clin Oncol 119(2):121-126, 1992.
  4. Scotlandi K., Baldini N., Campanacci M., Lollini P.L., Picci P., Serra M. Induction of HLA class II antigens in osteosarcoma cells by interferons and tumor necrosis factor alpha. Anticancer Res 12(3):767-772, 1992.
  5. Scotlandi K., Serra M., Landuzzi L., Baldini N. SARG: a new human osteosarcoma cell line. Expression of bone markers and of major histocompatibility antigens. Ann Oncol 3 Suppl 2:S29-31, 1992.
  6. Serra M., Morini M.C., Scotlandi K., Fisher L.W., Zini N., Colombo M.P., Campanacci M., Maraldi N.M., Olivari S., Baldini N. Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. Hum Pathol 23(12):1326-1331, 1992.
  7. De Mattei M., Martini M., Corallini A., Barbanti-Brodano G., Gerosa M., Iuzzolino P., Ghimenton C., Serra M., Baldini N., Tognon M. Detection of DNA sequences specific for BKV-early region and its expression in human tumors. Minerva Biotecnologica 5:181-186, 1993.
  8. Paniccia R., Colucci S., Grano M., Serra M., Zambonin-Zallone A., Teti A. Immediate cell signal by bone-related peptides in human osteoclast-like cells. American Journal of Physiology (Cell Physiology) 265:C1289-C1297, 1993.
  9. Scotlandi K., Serra M., Manara M.C., Nanni P., Nicoletti G., Landuzzi L., Maurici D., Baldini N. Human osteosarcoma cells, tumorigenic in nude mice, express b1 integrins and low levels of alkaline phosphatase activity. International Journal of Oncology 3:963-969, 1993.
  10. Serra M., Scotlandi K., Manara M.C., Maurici D., Lollini P.L., De Giovanni C., Toffoli G., Baldini N. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 13(2):323-329, 1993.
  11. De Mattei M., Martini F., Tognon M., Serra M., Baldini N., Barbanti-Brodano G. Polyomavirus latency and human tumors. Journal of Infectious Diseases 169:1175-1176, 1994.
  12. Giovannini M., Biegel J.A., Serra M., Wang J.Y., Wei Y.H., Nycum L., Emanuel B.S., Evans G.A. EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. Journal of Clinical Investigation 94:489-496, 1994.
  13. Grano M., Colucci S., De Bellis M., Zigrino P., Argentino A., Zambonin G., Serra M., Scotlandi K., Teti A., Zambonin-Zallone A. A new model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone. Journal of Bone and Mineral Research 9:1013-1020, 1994.
  14. Grano M., Zigrino P., Colucci S., Zambonin G., Trusolino L., Serra M., Baldini N., Teti A., Marchisio P.C., Zambonin-Zallone A. Adhesion properties and integrin expression of cultured human osteocalst-like cells. Experimental Cell Research 212:209-218, 1994.
  15. Scotlandi K., Serra M., Manara M.C., Lollini P.L., Maurici D., Del Bufalo D., Baldini N. Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. Int J Cancer 58(1):95-101, 1994.
  16. Baldini N., Scotlandi K., Barbanti-Brodano G., Manara M.C., Maurici D., Bacci G., Bertoni F., Picci P., Sottili S., Campanacci M., Serra M. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. New England Journal of Medicine 333:1380-1385, 1995.
  17. Baldini N., Scotlandi K., Serra M., Shikita T., Zini N., Ognibene A., Santi S., Ferracini R., Maraldi N.M. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol 68(3):226-239, 1995.
  18. Manara M., Scotlandi K., Serra M., Maurici D., Sarti M., Campanacci M., Baldini N. Absence of stimulatory effect of G-CSF on the growth of human sarcoma-cells. Int J Oncol 6(5):1011-1014, 1995.
  19. Scotlandi K., Serra M., Manara M.C., Maurici D., Benini S., Nini G., Campanacci M., Baldini N. Clinical relevance of Ki-67 expression in bone tumors. Cancer 75(3):806-814, 1995.
  20. Serra M., Scotlandi K., Manara M.C., Maurici D., Benini S., Sarti M., Campanacci M., Baldini N. Analysis of P-glycoprotein expression in osteosarcoma. Eur J Cancer 31A(12):1998-2002, 1995.
  21. Giovannini M., Strippoli P., Serra M., Sironi M., Fincato G., Colotta F., Bonafe M., Biunno I., Mantovani A., Orlandini S., Brandi M., Pastano R., Bagnara G. Production of interleukin-6 by human osteoclast-like cells from giant cell tumor of bone. Int J Oncol 8(2):297-303, 1996.
  22. Maraldi N.M., Zini N., Sabatelli P., Valmori A., Scotlandi K., Serra M., Baldini N. Ultrastructural features and P-glycoprotein immunolocalization in Saos-2/DX580 multidrug-resistant human osteosarcoma cells. J Submicrosc Cytol Pathol 28:93-100, 1996.
  23. Scotlandi K., Baldini N., Oliviero M., Di Renzo M.F., Martano M., Serra M., Manara M.C., Comoglio P.M., Ferracini R. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 149(4):1209-1219, 1996.
  24. Scotlandi K., Benini S., Sarti M., Serra M., Lollini P.L., Maurici D., Picci P., Manara M.C., Baldini N. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 56(20):4570-4574, 1996.
  25. Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.L., Picci P., Bertoni F., Baldini N. Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Hum Pathol 27(4):408-416, 1996.
  26. Scotlandi K., Serra M., Nicoletti G., Vaccari M., Manara M.C., Nini G., Landuzzi L., Colacci A., Bacci G., Bertoni F., Picci P., Campanacci M., Baldini N. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56(10):2434-2439, 1996.
  27. Serra M., Scotlandi K., Manara M.C., Maurici D., Benini S., Sarti M., Nini G., Barbanti-Brodano G., Baldini N. Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. Cytotechnology 19(3):253-256, 1996.
  28. Serra M., Scotlandi K., Sollazzo M.R., Sarti M., Maurici D., Benini S., Picci P., Bertoni F., Baldini N. Value of immunohistochemical detection of noncollagenous proteins of bone for the diagnosis of bone tumours. International Journal of Oncology 9:257-261, 1996.
  29. Zini N., Ognibene A., Bavelloni A., Santi S., Sabatelli P., Baldini N., Scotlandi K., Serra M., Maraldi N.M. Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells. Histochemistry and Cell Biology 106:457-464, 1996.
  30. Gasbarrini A., Grigolo B., Serra M., Baldini N., Scotlandi K., Gasbarrini A., Bernardi M., Facchini A. Free radicals generation during anoxia/reoxygenation in perfused osteoblast-like cells. Clinical Orthopaedics and Related Research 338:247-252, 1997.
  31. Tsuji Y., Kusuzaki K., Hirasawa Y., Serra M., Baldini N. Ki-67 antigen retrieval in formalin-fixed or ethanol-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining with autoclave treatment. Acta Histochemistry and Cytochemistry 30:251-255, 1997.
  32. Colucci S., Minielli V., Zambonin G., Cirulli N., Mori G., Serra M., Zambonin-Zallone A., Grano M. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone proteins coated surfaces. Calcified Tissue International 63:230-235, 1998.
  33. Lollini P.-L., Landuzzi L., Frabetti F., Rossi I., Nicoletti G., Scotlandi K., Serra M., Baldini N., De Giovanni C., Nanni P. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clinical Cancer Research 4:1843-1849, 1998.
  34. Maurici D., Perez-Atayde A., Grier H.E., Baldini N., Serra M., Fletcher J.A. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet Cytogenet 100(2):106-110, 1998.
  35. Scotlandi K., Benini S., Nanni P., Lollini P.L., Nicoletti G., Landuzzi L., Serra M., Manara M.C., Picci P., Baldini N. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 58(18):4127-4131, 1998.
  36. Szymanska J., Serra M., Skytting B., Larsson O., Virolainen M., Åkerman M., Tarkkanen M., Huuhtanen R., Picci P., Bacchini P., Asko-Seljavaara S., Elomaa I., Knuutila S. Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. Genes Chromosomes & Cancer 23:213-219, 1998.
  37. Tsuji Y., Kusuzaki K., Hirasawa Y., Serra M., Baldini N., Campanacci M. Retinoblastoma susceptibility gene product retrieval in formalin-fixed, paraffin-embedded tissue: a heating method for enhancing immunohistochemical staining. Acta Histochemica et Cytochemica 31:193-196, 1998.
  38. Baldini N., Scotlandi K., Serra M., Picci P., Bacci G., Sottili S., Campanacci M. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res 17(5):629-632, 1999.
  39. Benini S., Baldini N., Manara M.C., Chano T., Serra M., Rizzi S., Lollini P.L., Picci P., Scotlandi K. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 80(4):581-588, 1999.
  40. Jaeger V., Schneider-Stock R., Gerresheim F., Epplen J.T., Serra M., Lippert H., Roessner A. Myxoid liposarcoma with transition to round-cell lesion-cell cycle regulator genes and telomerase activity characterizing tumor progression: a case report. Human Pathology 30:1515-1519, 1999.
  41. Maraldi N.M., Zini N., Santi S., Scotlandi K., Serra M., Baldini N. P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Biology of the Cell 91:17-28, 1999.
  42. Scotlandi K., Manara M.C., Serra M., Benini S., Maurici D., Caputo A., De Giovanni C., Lollini P.L., Nanni P., Picci P., Campanacci M., Baldini N. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene 18(3):739-746, 1999.
  43. Serra M., Maurici D., Scotlandi K., Barbanti-Brodano G., Manara M.C., Benini S., Picci P., Bertoni F., Bacci G., Sottili S., Baldini N. Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma. Int J Oncol 14(2):301-307, 1999.
  44. Buonamici L., Serra M., Losi L., Eusebi V. Application of CARD-ISH for assessment of numerical chromosome aberrations in interphase nuclei of human tumor cells. International Journal of Surgical Pathology 8:201-206, 2000.
  45. Landuzzi L., De Giovanni C., Nicoletti G., Rossi I., Ricci C., Astolfi A., Scotlandi K., Serra M., Vitale L., Bagnara G.P., Nanni P., Lollini P.-L. The metastatic ability of Ewing's sarcoma cells is modulated by Stem Cell Factor and by its receptor c-kit. American Journal of Pathology 157:2123-2131, 2000.
  46. Manara M.C., Baldini N., Serra M., Lollini P.L., De Giovanni C., Vaccari M., Argnani A., Benini S., Maurici D., Picci P., Scotlandi K. Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone 26(3):215-220, 2000.
  47. Scotlandi K., Baldini N., Cerisano V., Manara M.C., Benini S., Serra M., Lollini P.L., Nanni P., Nicoletti G., Bernard G., Bernard A., Picci P. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 60(18):5134-5142, 2000.
  48. Scotlandi K., Benini S., Manara M.C., Serra M., Nanni P., Lollini P.L., Nicoletti G., Landuzzi L., Chano T., Picci P., Baldini N. Murine model for skeletal metastases of Ewing's sarcoma. J Orthop Res 18(6):959-966, 2000.
  49. Scotlandi K., Chano T., Benini S., Serra M., Manara M.C., Cerisano V., Picci P., Baldini N. Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone. Int J Cancer 87(3):328-335, 2000.
  50. Shen J.-N., Scotlandi K., Baldini N., Manara M.C., Benini S., Cerisano V., Picci P., Serra M. Prognostic significance of nuclear accumulation of c-myc and mdm2 proteins in synovial sarcoma of the extremities. Oncology 58(3):253-260, 2000.
  51. Wolf M., El-Rifai W., Tarkkanen M., Kononen J., Serra M., Eriksen E.F., Elomaa I., Kallionemi A., Kallionemi O.-P., Knuutila S. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genetics and Cytogenetics 123:128-132, 2000.
  52. Benini S., Manara M.C., Baldini N., Cerisano V., Serra M., Mercuri M., Lollini P.-L., Nanni P., Picci P., Scotlandi K. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clinical Cancer Research 7:1790-1797, 2001.
  53. Serra M., Tarkkanen M., Baldini N., Scotlandi K., Sarti M., Maurici D., Manara M.C., Benini S., Bacchini P., Knuutila S., Picci P. Simultaneous paired analysis of numerical chromosomal aberrations and DNA content in osteosarcoma. Mod Pathol 14(7):710-716, 2001.
  54. Chano T., Saeki Y., Serra M., Matsumoto K., Okabe H. Preferential expression of RB1-inducible coiled-coil 1 in terminal differentiated musculoskeletal cells. American Journal of Pathology 161:359-364, 2002.
  55. Manara M.C., Perbal B., Benini S., Strammiello R., Cerisano V., Perdichizzi S., Serra M., Astolfi A., Bertoni F., Alami J., Yeger H., Picci P., Scotlandi K. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol 160(3):849-859, 2002.
  56. Martini F., Lazzarin L., Iaccheri L., Vignocchi B., Finocchiaro G., Magnani I., Serra M., Scotlandi K., Barbanti-Brodano G., Tognon M. Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer 94:1037-1048, 2002.
  57. Meza-Zepeda L.A., Forus A., Lygren B., Dahlberg A.B., Godager L.H., South A.P., Marenholz I., Lioumi M., Florenes V.A., Maelandsmo G.M., Serra M., Mischke D., Nizetic D., Ragoussis J., Tarkkanen M., Nesland J.M., Knuutila S., Myklebost O. Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene 21:2261-2269, 2002.
  58. Scotlandi K., Avnet S., Benini S., Manara M.C., Serra M., Cerisano V., Perdichizzi S., Lollini P.L., De Giovanni C., Landuzzi L., Picci P. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 101(1):11-16, 2002.
  59. Scotlandi K., Maini C., Manara M.C., Benini S., Serra M., Cerisano V., Strammiello R., Baldini N., Lollini P.L., Nanni P., Nicoletti G., Picci P. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 9(3):296-307, 2002.
  60. Scotlandi K., Perdichizzi S., Manara M.C., Serra M., Benini S., Cerisano V., Strammiello R., Mercuri M., Reverter-Branchat G., Faircloth G., D'Incalci M., Picci P. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 8(12):3893-3903, 2002.
  61. Gamberi G., Serra M., Ragazzini P., Magagnoli G., Pazzaglia L., Ponticelli F., Ferrari C., Zanasi M., Bertoni F., Picci P., Benassi M.S. Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep 10(2):351-356, 2003.
  62. Hattinger C.M., Reverter-Branchat G., Remondini D., Castellani G.C., Benini S., Pasello M., Manara M.C., Scotlandi K., Picci P., Serra M. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 82(9):483-493, 2003.
  63. Picci P., Scotlandi K., Serra M. The role of basic research in clinical treatment of Ewing's sarcoma and osteosarcoma. Chir Organi Mov 88(2):201-209, 2003.
  64. Scotlandi K., Manara M.C., Strammiello R., Landuzzi L., Benini S., Perdichizzi S., Serra M., Astolfi A., Nicoletti G., Lollini P.L., Bertoni F., Nanni P., Picci P. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 21(10):1952-1960, 2003.
  65. Serra M., Scotlandi K., Reverter-Branchat G., Ferrari S., Manara M.C., Benini S., Incaprera M., Bertoni F., Mercuri M., Briccoli A., Bacci G., Picci P. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 21(3):536-542, 2003.
  66. Strammiello R., Benini S., Manara M.C., Perdichizzi S., Serra M., Spisni E., Picci P., Scotlandi K. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Horm Metab Res 35(11-12):675-684, 2003.
  67. Benini S., Manara M.C., Cerisano V., Perdichizzi S., Strammiello R., Serra M., Picci P., Scotlandi K. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 108(3):358-366, 2004.
  68. Chano T., KanJi M., Scotlandi K., Benini S., Lapucci C., Manara M.C., Serra M., Picci P., Okabe H., Baldini N. Differentially expressed genes in multidrug resistant variants of U-2OS human osteosarcoma cells. Oncology Reports 11:1254-1263, 2004.
  69. Hattinger C.M., Tarkkanen M., Benini S., Pasello M., Stoico G., Bacchini P., Knuutila S., Scotlandi K., Picci P., Serra M. Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. Eur J Cell Biol 83(9):483-491, 2004.
  70. Manara M.C., Serra M., Benini S., Picci P., Scotlandi K. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 24(2):365-372, 2004.
  71. Ragazzini P., Gamberi G., Pazzaglia L., Serra M., Magagnoli G., Ponticelli F., Ferrari C., Ghinelli C., Alberghini M., Bertoni F., Picci P., Benassi M.S. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol Histopathol 19(2):401-411, 2004.
  72. Serra M., Reverter-Branchat G., Maurici D., Benini S., Shen J.N., Chano T., Hattinger C.M., Manara M.C., Pasello M., Scotlandi K., Picci P. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15(1):151-160, 2004.
  73. Atiye J., Wolf M., Kaur S., Monni O., Bohling T., Kivioja A., Tas E., Serra M., Tarkkanen M., Knuutila S. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42:158-163, 2005.
  74. Benini S., Perbal B., Zambelli D., Colombo M.P., Manara M.C., Serra M., Parenza M., Martinez V., Picci P., Scotlandi K. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24(27):4349-4361, 2005.
  75. Manara M.C., Perdichizzi S., Serra M., Pierini R., Benini S., Hattinger C.M., Astolfi A., Bagnati R., D'Incalci M., Picci P., Scotlandi K. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 27(6):1605-1616, 2005.
  76. Pasello M., Hattinger C.M., Stoico G., Manara M.C., Benini S., Geroni C., Mercuri M., Scotlandi K., Picci P., Serra M. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. Eur J Cancer 41(14):2184-2195, 2005.
  77. Scotlandi K., Manara M.C., Hattinger C.M., Benini S., Perdichizzi S., Pasello M., Bacci G., Zanella L., Bertoni F., Picci P., Serra M. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 41(9):1349-1361, 2005.
  78. Scotlandi K., Manara M.C., Nicoletti G., Lollini P.L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., Garcia-Echeverria C., Hofmann F., Picci P. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65(9):3868-3876, 2005.
  79. Bacci G., Loro L., Longhi A., Bertoni F., Bacchini P., Versari M., Picci P., Serra M. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Anticancer Drugs 17(4):411-415, 2006.
  80. Manara M.C., Bernard G., Lollini P.L., Nanni P., Zuntini M., Landuzzi L., Benini S., Lattanzi G., Sciandra M., Serra M., Colombo M.P., Bernard A., Picci P., Scotlandi K. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 17(4):1910-1921, 2006.
  81. Picci P., Scotlandi K., Serra M., Rizzi A. Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS). Adv Exp Med Biol 587:1-12, 2006.
  82. Serra M., Pasello M., Manara M.C., Scotlandi K., Ferrari S., Bertoni F., Mercuri M., Alvegard T.A., Picci P., Bacci G., Smeland S. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol 29(6):1459-1468, 2006.
  83. Tarkkanen M., Larramendy M.L., Bohling T., Serra M., Hattinger C.M., Kivioja A., Elomaa I., Picci P., Knuutila S. Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. European Journal of Cancer 42:1172-1180, 2006.
  84. Bacci G., Balladelli A., Forni C., Ferrari S., Longhi A., Benassi M.S., Briccoli A., Serra M., Picci P. Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Ann Oncol 18(12):2037-2040, 2007.
  85. Bacci G., Balladelli A., Forni C., Longhi A., Serra M., Fabbri N., Alberghini M., Ferrari S., Benassi M.S., Picci P. Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours. J Bone Joint Surg Br 89(9):1229-1233, 2007.
  86. Bacci G., Ferrari S., Mercuri M., Longhi A., Fabbri N., Galletti S., Forni C., Balladelli A., Serra M., Picci P. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop 78(3):377-384, 2007.
  87. Bacci G., Forni C., Longhi A., Ferrari S., Mercuri M., Bertoni F., Serra M., Briccoli A., Balladelli A., Picci P. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 96(2):118-123, 2007.
  88. Brusa G., Zuffa E., Hattinger C.M., Serra M., Remondini D., Castellani G.C., Righi S., Campidelli C., Pileri S., Zinzani P.L., Gabriele A., Mancini M., Corrado P., Barbieri E., Santucci M.A. Genomic imbalances associated with secondary acure leukemias in Hodgkin lymphoma. Oncology Reports 18:1427-1434, 2007.
  89. Cantiani L., Manara M.C., Zucchini C., De Sanctis P., Zuntini M., Valvassori L., Serra M., Olivero M., Di Renzo M.F., Colombo M.P., Picci P., Scotlandi K. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res 67(16):7675-7685, 2007.
  90. Serra M., Picci P., Ferrari S., Bacci G. Prognostic value of P-glycoprotein in high-grade osteosarcoma (Letter to Editor). Journal of Clinical Oncology 25:4858-4860, 2007.
  91. Pasello M., Michelacci F., Scionti I., Hattinger C.M., Zuntini M., Caccuri A.M., Scotlandi K., Picci P., Serra M. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 68(16):6661-6668, 2008.
  92. Perbal B., Zuntini M., Zambelli D., Serra M., Sciandra M., Cantiani L., Lucarelli E., Picci P., Scotlandi K. Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res 14(3):701-709, 2008.
  93. Scionti I., Michelacci F., Pasello M., Hattinger C.M., Alberghini M., Manara M.C., Bacci G., Ferrari S., Scotlandi K., Picci P., Serra M. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann Oncol 19(8):1500-1508, 2008.
  94. Hattinger C.M., Stoico G., Michelacci F., Pasello M., Scionti I., Remondini D., Castellani G.C., Fanelli M., Scotlandi K., Picci P., Serra M. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 48(4):289-309, 2009.
  95. Kresse S.H., Ohnstad H.O., Paulsen E.B., Bjerkehagen B., Szuhai K., Serra M., Schaefer K.L., Myklebost O., Meza-Zepeda L.A. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes Cancer 48(8):679-693, 2009.
  96. Savola S., Klami A., Tripathi A., Niini T., Serra M., Picci P., Kaski S., Zambelli D., Scotlandi K., Knuutila S. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 9:17, 2009.
  97. Scotlandi K., Remondini D., Castellani G., Manara M.C., Nardi F., Cantiani L., Francesconi M., Mercuri M., Caccuri A.M., Serra M., Knuutila S., Picci P. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 27(13):2209-2216, 2009.
  98. Serra M., Scotlandi K. Caveolins in the development and diseases of musculoskeletal system. Cancer Lett 284(2):113-121, 2009.
  99. Toffoli G., Biason P., Russo A., De Mattia E., Cecchin E., Hattinger C.M., Pasello M., Alberghini M., Ferrari C., Scotlandi K., Picci P., Serra M. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 15(10):3550-3556, 2009.
  100. Hattinger C.M., Pasello M., Ferrari S., Picci P., Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15(4):615-634, 2010.
  101. Niini T., Lopez-Guerrero J.A., Ninomiya S., Guled M., Hattinger C.M., Michelacci F., Bohling T., Llombart-Bosch A., Picci P., Serra M., Knuutila S. Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. Genes Chromosomes Cancer 49(2):132-143, 2010.
  102. Ottaviano L., Schaefer K.L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.M., Hogendoorn P.C., Buerger H., Aigner T., Gabbert H.E., Poremba C. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49(1):40-51, 2010.
  103. Zambelli D., Zuntini M., Nardi F., Manara M.C., Serra M., Landuzzi L., Lollini P.L., Ferrari S., Alberghini M., Llombart-Bosch A., Piccolo E., Iacobelli S., Picci P., Scotlandi K. Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int J Cancer 126(1):41-52, 2010.
  104. Buddingh E.P., Kuijjer M.L., Duim R.A., Burger H., Agelopoulos K., Myklebost O., Serra M., Mertens F., Hogendoorn P.C., Lankester A.C., Cleton-Jansen A.M. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 17(8):2110-2119, 2011.
  105. Buddingh E.P., Schilham M.W., Ruslan S.E., Berghuis D., Szuhai K., Suurmond J., Taminiau A.H., Gelderblom H., Egeler R.M., Serra M., Hogendoorn P.C., Lankester A.C. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 60(4):575-586, 2011.
  106. Kuijjer M.L., Namlos H.M., Hauben E.I., Machado I., Kresse S.H., Serra M., Llombart-Bosch A., Hogendoorn P.C., Meza-Zepeda L.A., Myklebost O., Cleton-Jansen A.M. mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Med Genomics 4:66, 2011.
  107. Lopez-Guerrero J.A., Machado I., Scotlandi K., Noguera R., Pellin A., Navarro S., Serra M., Calabuig-Farinas S., Picci P., Llombart-Bosch A. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 128(5):1139-1150, 2011.
  108. Mohseny A.B., Machado I., Cai Y., Schaefer K.L., Serra M., Hogendoorn P.C., Llombart-Bosch A., Cleton-Jansen A.M. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 91(8):1195-1205, 2011.
  109. Niini T., Lahti L., Michelacci F., Ninomiya S., Hattinger C.M., Guled M., Bohling T., Picci P., Serra M., Knuutila S. Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. Genes Chromosomes Cancer 50(5):291-306, 2011.
  110. Pasello M., Manara M.C., Michelacci F., Fanelli M., Hattinger C.M., Nicoletti G., Landuzzi L., Lollini P.L., Caccuri A., Picci P., Scotlandi K., Serra M. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal Cell Pathol (Amst) 34(3):131-145, 2011.
  111. Scotlandi K., Manara M.C., Serra M., Marino M.T., Ventura S., Garofalo C., Alberghini M., Magagnoli G., Ferrari S., Lopez-Guerrero J.A., Llombard-Bosch A., Picci P. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer 47(8):1258-1266, 2011.
  112. Biason P., Hattinger C.M., Innocenti F., Talamini R., Alberghini M., Scotlandi K., Zanusso C., Serra M., Toffoli G. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J 12(6):476-483, 2012.
  113. Nakatani F., Ferracin M., Manara M.C., Ventura S., Del Monaco V., Ferrari S., Alberghini M., Grilli A., Knuutila S., Schaefer K.L., Mattia G., Negrini M., Picci P., Serra M., Scotlandi K. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226(5):796-805, 2012.
  114. Pahl J.H., Ruslan S.E., Buddingh E.P., Santos S.J., Szuhai K., Serra M., Gelderblom H., Hogendoorn P.C., Egeler R.M., Schilham M.W., Lankester A.C. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 18(2):432-441, 2012.
  115. Sau A., Filomeni G., Pezzola S., D'Aguanno S., Tregno F.P., Urbani A., Serra M., Pasello M., Picci P., Federici G., Caccuri A.M. Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Mol Biosyst 8(4):994-1006, 2012.
  116. Kuijjer M.L., Peterse E.F., van den Akker B.E., Briaire-de Bruijn I.H., Serra M., Meza-Zepeda L.A., Myklebost O., Hassan A.B., Hogendoorn P.C., Cleton-Jansen A.M. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 13:245, 2013.
  117. Savage S.A., Mirabello L., Wang Z., Gastier-Foster J.M., Gorlick R., Khanna C., Flanagan A.M., Tirabosco R., Andrulis I.L., Wunder J.S., Gokgoz N., Patino-Garcia A., Sierrasesumaga L., Lecanda F., Kurucu N., Ilhan I.E., Sari N., Serra M., Hattinger C., Picci P., Spector L.G., Barkauskas D.A., Marina N., de Toledo S.R., Petrilli A.S., Amary M.F., Halai D., Thomas D.M., Douglass C., Meltzer P.S., Jacobs K., Chung C.C., Berndt S.I., Purdue M.P., Caporaso N.E., Tucker M., Rothman N., Landi M.T., Silverman D.T., Kraft P., Hunter D.J., Malats N., Kogevinas M., Wacholder S., Troisi R., Helman L., Fraumeni J.F., Jr., Yeager M., Hoover R.N., Chanock S.J. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 45(7):799-803, 2013.
  118. Tavanti E., Sero V., Vella S., Fanelli M., Michelacci F., Landuzzi L., Magagnoli G., Versteeg R., Picci P., Hattinger C.M., Serra M. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer 109(10):2607-2618, 2013.
  119. De Luca A., Mei G., Rosato N., Nicolai E., Federici L., Palumbo C., Pastore A., Serra M., Caccuri A.M. The fine-tuning of TRAF2-GSTP1-1 interaction: effect of ligand binding and in situ detection of the complex. Cell Death Dis 5:e1015, 2014.
  120. Guerzoni C., Amatori S., Giorgi L., Manara M.C., Landuzzi L., Lollini P.L., Tassoni A., Balducci M., Manfrini M., Pratelli L., Serra M., Picci P., Magnani M., Fusi V., Fanelli M., Scotlandi K. An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer 14:137, 2014.
  121. Kuijjer M.L., van den Akker B.E., Hilhorst R., Mommersteeg M., Buddingh E.P., Serra M., Burger H., Hogendoorn P.C., Cleton-Jansen A.M. Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Med Genomics 7:4, 2014.
  122. Sarhadi V.K., Lahti L., Scheinin I., Ellonen P., Kettunen E., Serra M., Scotlandi K., Picci P., Knuutila S. Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias. Genes Chromosomes Cancer 53(7):579-588, 2014.
  123. Scheil-Bertram S., Kappler R., von Baer A., Hartwig E., Sarkar M., Serra M., Bruderlein S., Westhoff B., Melzner I., Bassaly B., Herms J., Hugo H.H., Schulte M., Moller P. Molecular profiling of chordoma. Int J Oncol 44(4):1041-1055, 2014.
  124. Sero V., Tavanti E., Vella S., Hattinger C.M., Fanelli M., Michelacci F., Versteeg R., Valsasina B., Gudeman B., Picci P., Serra M. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs 2014.
  125. Wang Z., Zhu B., Zhang M., Parikh H., Jia J., Chung C.C., Sampson J.N., Hoskins J.W., Hutchinson A., Burdette L., Ibrahim A., Hautman C., Raj P.S., Abnet C.C., Adjei A.A., Ahlbom A., Albanes D., Allen N.E., Ambrosone C.B., Aldrich M., Amiano P., Amos C., Andersson U., Andriole G., Jr., Andrulis I.L., Arici C., Arslan A.A., Austin M.A., Baris D., Barkauskas D.A., Bassig B.A., Beane Freeman L.E., Berg C.D., Berndt S.I., Bertazzi P.A., Biritwum R.B., Black A., Blot W., Boeing H., Boffetta P., Bolton K., Boutron-Ruault M.C., Bracci P.M., Brennan P., Brinton L.A., Brotzman M., Bueno-de-Mesquita H.B., Buring J.E., Butler M.A., Cai Q., Cancel-Tassin G., Canzian F., Cao G., Caporaso N.E., Carrato A., Carreon T., Carta A., Chang G.C., Chang I.S., Chang-Claude J., Che X., Chen C.J., Chen C.Y., Chen C.H., Chen C., Chen K.Y., Chen Y.M., Chokkalingam A.P., Chu L.W., Clavel-Chapelon F., Colditz G.A., Colt J.S., Conti D., Cook M.B., Cortessis V.K., Crawford E.D., Cussenot O., Davis F.G., De Vivo I., Deng X., Ding T., Dinney C.P., Di Stefano A.L., Diver W.R., Duell E.J., Elena J.W., Fan J.H., Feigelson H.S., Feychting M., Figueroa J.D., Flanagan A.M., Fraumeni J.F., Jr., Freedman N.D., Fridley B.L., Fuchs C.S., Gago-Dominguez M., Gallinger S., Gao Y.T., Gapstur S.M., Garcia-Closas M., Garcia-Closas R., Gastier-Foster J.M., Gaziano J.M., Gerhard D.S., Giffen C.A., Giles G.G., Gillanders E.M., Giovannucci E.L., Goggins M., Gokgoz N., Goldstein A.M., Gonzalez C., Gorlick R., Greene M.H., Gross M., Grossman H.B., Grubb R., 3rd, Gu J., Guan P., Haiman C.A., Hallmans G., Hankinson S.E., Harris C.C., Hartge P., Hattinger C., Hayes R.B., He Q., Helman L., Henderson B.E., Henriksson R., Hoffman-Bolton J., Hohensee C., Holly E.A., Hong Y.C., Hoover R.N., Hosgood H.D., 3rd, Hsiao C.F., Hsing A.W., Hsiung C.A., Hu N., Hu W., Hu Z., Huang M.S., Hunter D.J., Inskip P.D., Ito H., Jacobs E.J., Jacobs K.B., Jenab M., Ji B.T., Johansen C., Johansson M., Johnson A., Kaaks R., Kamat A.M., Kamineni A., Karagas M., Khanna C., Khaw K.T., Kim C., Kim I.S., Kim J.H., Kim Y.H., Kim Y.C., Kim Y.T., Kang C.H., Jung Y.J., Kitahara C.M., Klein A.P., Klein R., Kogevinas M., Koh W.P., Kohno T., Kolonel L.N., Kooperberg C., Kratz C.P., Krogh V., Kunitoh H., Kurtz R.C., Kurucu N., Lan Q., Lathrop M., Lau C.C., Lecanda F., Lee K.M., Lee M.P., Le Marchand L., Lerner S.P., Li D., Liao L.M., Lim W.Y., Lin D., Lin J., Lindstrom S., Linet M.S., Lissowska J., Liu J., Ljungberg B., Lloreta J., Lu D., Ma J., Malats N., Mannisto S., Marina N., Mastrangelo G., Matsuo K., McGlynn K.A., McKean-Cowdin R., McNeill L.H., McWilliams R.R., Melin B.S., Meltzer P.S., Mensah J.E., Miao X., Michaud D.S., Mondul A.M., Moore L.E., Muir K., Niwa S., Olson S.H., Orr N., Panico S., Park J.Y., Patel A.V., Patino-Garcia A., Pavanello S., Peeters P.H., Peplonska B., Peters U., Petersen G.M., Picci P., Pike M.C., Porru S., Prescott J., Pu X., Purdue M.P., Qiao Y.L., Rajaraman P., Riboli E., Risch H.A., Rodabough R.J., Rothman N., Ruder A.M., Ryu J.S., Sanson M., Schned A., Schumacher F.R., Schwartz A.G., Schwartz K.L., Schwenn M., Scotlandi K., Seow A., Serra C., Serra M., Sesso H.D., Severi G., Shen H., Shen M., Shete S., Shiraishi K., Shu X.O., Siddiq A., Sierrasesumaga L., Sierri S., Loon Sihoe A.D., Silverman D.T., Simon M., Southey M.C., Spector L., Spitz M., Stampfer M., Stattin P., Stern M.C., Stevens V.L., Stolzenberg-Solomon R.Z., Stram D.O., Strom S.S., Su W.C., Sund M., Sung S.W., Swerdlow A., Tan W., Tanaka H., Tang W., Tang Z.Z., Tardon A., Tay E., Taylor P.R., Tettey Y., Thomas D.M., Tirabosco R., Tjonneland A., Tobias G.S., Toro J.R., Travis R.C., Trichopoulos D., Troisi R., Truelove A., Tsai Y.H., Tucker M.A., Tumino R., Van Den Berg D., Van Den Eeden S.K., Vermeulen R., Vineis P., Visvanathan K., Vogel U., Wang C., Wang J., Wang S.S., Weiderpass E., Weinstein S.J., Wentzensen N., Wheeler W., White E., Wiencke J.K., Wolk A., Wolpin B.M., Wong M.P., Wrensch M., Wu C., Wu T., Wu X., Wu Y.L., Wunder J.S., Xiang Y.B., Xu J., Yang H.P., Yang P.C., Yatabe Y., Ye Y., Yeboah E.D., Yin Z., Ying C., Yu C.J., Yu K., Yuan J.M., Zanetti K.A., Zeleniuch-Jacquotte A., Zheng W., Zhou B., Mirabello L., Savage S.A., Kraft P., Chanock S.J., Yeager M., Landi M.T., Shi J., Chatterjee N., Amundadottir L.T. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet 23(24):6616-6633, 2014.
  126. Ferrari S., Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother 16(18):2727-2736, 2015.
  127. Hattinger C.M., Fanelli M., Tavanti E., Vella S., Ferrari S., Picci P., Serra M. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs 20(3):495-514, 2015.
  128. Hattinger C.M., Michelacci F., Sella F., Magagnoli G., Benini S., Gambarotti M., Palmerini E., Picci P., Serra M., Ferrari S. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy. Histopathology 67(3):338-347, 2015.
  129. Hattinger C.M., Serra M. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma. Expert Opin Drug Metab Toxicol 11(9):1449-1463, 2015.
  130. Mirabello L., Koster R., Moriarity B.S., Spector L.G., Meltzer P.S., Gary J., Machiela M.J., Pankratz N., Panagiotou O.A., Largaespada D., Wang Z., Gastier-Foster J.M., Gorlick R., Khanna C., de Toledo S.R., Petrilli A.S., Patino-Garcia A., Sierrasesumaga L., Lecanda F., Andrulis I.L., Wunder J.S., Gokgoz N., Serra M., Hattinger C., Picci P., Scotlandi K., Flanagan A.M., Tirabosco R., Amary M.F., Halai D., Ballinger M.L., Thomas D.M., Davis S., Barkauskas D.A., Marina N., Helman L., Otto G.M., Becklin K.L., Wolf N.K., Weg M.T., Tucker M., Wacholder S., Fraumeni J.F., Jr., Caporaso N.E., Boland J.F., Hicks B.D., Vogt A., Burdett L., Yeager M., Hoover R.N., Chanock S.J., Savage S.A. A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov 5(9):920-931, 2015.
  131. Buondonno I., Gazzano E., Jean S.R., Audrito V., Kopecka J., Fanelli M., Salaroglio I.C., Costamagna C., Roato I., Mungo E., Hattinger C.M., Deaglio S., Kelley S.O., Serra M., Riganti C. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. Mol Cancer Ther 15(11):2640-2652, 2016.
  132. Chegaev K., Rolando B., Cortese D., Gazzano E., Buondonno I., Lazzarato L., Fanelli M., Hattinger C.M., Serra M., Riganti C., Fruttero R., Ghigo D., Gasco A. H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. J Med Chem 59(10):4881-4889, 2016.
  133. Fanelli M., Hattinger C.M., Vella S., Tavanti E., Michelacci F., Gudeman B., Barnett D., Picci P., Serra M. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1((R)) can Overcome Drug Resistance in Osteosarcoma. Curr Cancer Drug Targets 16(3):261-274, 2016.
  134. Hattinger C.M., Biason P., Iacoboni E., Gagno S., Fanelli M., Tavanti E., Vella S., Ferrari S., Roli A., Roncato R., Giodini L., Scotlandi K., Picci P., Toffoli G., Serra M. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget 7(38):61970-61987, 2016.
  135. Ruiz-Pinto S., Pita G., Patino-Garcia A., Garcia-Miguel P., Alonso J., Perez-Martinez A., Sastre A., Gomez-Mariano G., Lissat A., Scotlandi K., Serra M., Ladenstein R., Lapouble E., Pierron G., Kontny U., Picci P., Kovar H., Delattre O., Gonzalez-Neira A. Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome. Ann Oncol 27(9):1788-1793, 2016.
  136. Sampson J.N., Wheeler W.A., Yeager M., Panagiotou O., Wang Z., Berndt S.I., Lan Q., Abnet C.C., Amundadottir L.T., Figueroa J.D., Landi M.T., Mirabello L., Savage S.A., Taylor P.R., De Vivo I., McGlynn K.A., Purdue M.P., Rajaraman P., Adami H.O., Ahlbom A., Albanes D., Amary M.F., An S.J., Andersson U., Andriole G., Andrulis I.L., Angelucci E., Ansell S.M., Arici C., Armstrong B.K., Arslan A.A., Austin M.A., Baris D., Barkauskas D.A., Bassig B.A., Becker N., Benavente Y., Benhamou S., Berg C., Van Den Berg D., Bernstein L., Bertrand K.A., Birmann B.M., Black A., Boeing H., Boffetta P., Boutron-Ruault M.C., Bracci P.M., Brinton L., Brooks-Wilson A.R., Bueno-De-Mesquita H.B., Burdett L., Buring J., Butler M.A., Cai Q., Cancel-Tassin G., Canzian F., Carrato A., Carreon T., Carta A., Chan J.K.C., Chang E.T., Chang G.C., Chang I.S., Chang J., Chang-Claude J., Chen C.J., Chen C.Y., Chen C., Chen C.H., Chen H., Chen K., Chen K.Y., Chen K.C., Chen Y., Chen Y.H., Chen Y.S., Chen Y.M., Chien L.H., Chirlaque M.D., Choi J.E., Choi Y.Y., Chow W.H., Chung C.C., Clavel J., Clavel-Chapelon F., Cocco P., Colt J.S., Comperat E., Conde L., Connors J.M., Conti D., Cortessis V.K., Cotterchio M., Cozen W., Crouch S., Crous-Bou M., Cussenot O., Davis F.G., Ding T., Diver W.R., Dorronsoro M., Dossus L., Duell E.J., Ennas M.G., Erickson R.L., Feychting M., Flanagan A.M., Foretova L., Fraumeni J.F., Freedman N.D., Freeman L.E.B., Fuchs C., Gago-Dominguez M., Gallinger S., Gao Y.T., Gapstur S.M., Garcia-Closas M., García-Closas R., Gascoyne R.D., Gastier-Foster J., Gaudet M.M., Gaziano J.M., Giffen C., Giles G.G., Giovannucci E., Glimelius B., Goggins M., Gokgoz N., Goldstein A.M., Gorlick R., Gross M., Grubb R., Gu J., Guan P., Gunter M., Guo H., Habermann T.M., Haiman C.A., Halai D., Hallmans G., Hassan M., Hattinger C., He Q., He X., Helzlsouer K., Henderson B., Henriksson R., Hjalgrim H., Hoffman-Bolton J., Hohensee C., Holford T.R., Holly E.A., Hong Y.C., Hoover R.N., Horn-Ross P.L., Hosain G.M.M., Hosgood H.D., Hsiao C.F., Hu N., Hu W., Hu Z., Huang M.S., Huerta J.M., Hung J.Y., Hutchinson A., Inskip P.D., Jackson R.D., Jacobs E.J., Jenab M., Jeon H.S., Ji B.T., Jin G., Jin L., Johansen C., Johnson A., Jung Y.J., Kaaks R., Kamineni A., Kane E., Kang C.H., Karagas M.R., Kelly R.S., Khaw K.T., Kim C., Kim H.N., Kim J.H., Kim J.S., Kim Y.H., Kim Y.T., Kim Y.C., Kitahara C.M., Klein A.P., Klein R.J., Kogevinas M., Kohno T., Kolonel L.N., Kooperberg C., Kricker A., Krogh V., Kunitoh H., Kurtz R.C., Kweon S.S., La Croix A., Lawrence C., Lecanda F., Lee V.H.F., Li D., Li H., Li J., Li Y.J., Li Y., Liao L.M., Liebow M., Lightfoot T., Lim W.Y., Lin C.C., Lin D., Lindstrom S., Linet M.S., Link B.K., Liu C., Liu J., Liu L., Ljungberg B., Lloreta J., Di Lollo S., Lu D., Lund E., Malats N., Mannisto S., Marchand L.L., Marina N., Masala G., Mastrangelo G., Matsuo K., Maynadie M., McKay J., McKean-Cowdin R., Melbye M., Melin B.S., Michaud D.S., Mitsudomi T., Monnereau A., Montalvan R., Moore L.E., Mortensen L.M., Nieters A., North K.E., Novak A.J., Oberg A.L., Offit K., Oh I.J., Olson S.H., Palli D., Pao W., Park I.K., Park J.Y., Park K.H., Patiño-Garcia A., Pavanello S., Peeters P.H.M., Perng R.P., Peters U., Petersen G.M., Picci P., Pike M.C., Porru S., Prescott J., Prokunina-Olsson L., Qian B., Qiao Y.L., Rais M., Riboli E., Riby J., Risch H.A., Rizzato C., Rodabough R., Roman E., Roupret M., Ruder A.M., De Sanjose S., Scelo G., Schned A., Schumacher F., Schwartz K., Schwenn M., Scotlandi K., Seow A., Serra C., Serra M., Sesso H.D., Setiawan V.W., Severi G., Severson R.K., Shanafelt T.D., Shen H., Shen W., Shin M.H., Shiraishi K., Shu X.O., Siddiq A., Sierrasesúmaga L., Sihoe A.D.L., Skibola C.F., Smith A., Smith M.T., Southey M.C., Spinelli J.J., Staines A., Stampfer M., Stern M.C., Stevens V.L., Stolzenberg-Solomon R.S., Su J., Su W.C., Sund M., Sung J.S., Sung S.W., Tan W., Tang W., Tardón A., Thomas D., Thompson C.A., Tinker L.F., Tirabosco R., Tjønneland A., Travis R.C., Trichopoulos D., Tsai F.Y., Tsai Y.H., Tucker M., Turner J., Vajdic C.M., Vermeulen R.C.H., Villano D.J., Vineis P., Virtamo J., Visvanathan K., Wactawski-Wende J., Wang C., Wang C.L., Wang J.C., Wang J., Wei F., Weiderpass E., Weiner G.J., Weinstein S., Wentzensen N., White E., Witzig T.E., Wolpin B.M., Wong M.P., Wu C., Wu G., Wu J., Wu T., Wu W., Wu X., Wu Y.L., Wunder J.S., Xiang Y.B., Xu J., Xu P., Yang P.C., Yang T.Y., Ye Y., Yin Z., Yokota J., Yoon H.I., Yu C.J., Yu H., Yu K., Yuan J.M., Zelenetz A., Zeleniuch-Jacquotte A., Zhang X.C., Zhang Y., Zhao X., Zhao Z., Zheng H., Zheng T., Zheng W., Zhou B., Zhu M., Zucca M., Boca S.M., Cerhan J.R., Ferri G.M., Hartge P., Hsiung C.A., Magnani C., Miligi L., Morton L.M., Smedby K.E., Teras L.R., Vijai J., Wang S.S., Brennan P., Caporaso N.E., Hunter D.J., Kraft P., Rothman N., Silverman D.T., Slager S.L., Chanock S.J., Chatterjee N. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types. Journal of the National Cancer Institute 107(12) 2016.
  137. Hattinger C.M., Fanelli M., Tavanti E., Vella S., Riganti C., Picci P., Serra M. Doxorubicin-resistant osteosarcoma: Novel therapeutic approaches in sight? Future Oncology 13(8):673-677, 2017.
  138. Hattinger C.M., Fanelli M., Tavanti E., Vella S., Riganti C., Picci P., Serra M. Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight? Future Oncol 13(8):673-677, 2017.
  139. Hattinger C.M., Tavanti E., Fanelli M., Vella S., Picci P., Serra M. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Expert Opinion on Drug Metabolism and Toxicology 13(3):245-257, 2017.
  140. Serra M., Hattinger C.M. Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcoma. Expert Opinion on Drug Metabolism and Toxicology 13(1):123, 2017.
  141. Serra M., Hattinger C.M. The pharmacogenomics of osteosarcoma. Pharmacogenomics J 17(1):11-20, 2017.
  142. Buondonno I., Gazzano E., Tavanti E., Chegaev K., Kopecka J., Fanelli M., Rolando B., Fruttero R., Gasco A., Hattinger C., Serra M., Riganti C. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. Cell Mol Life Sci 2018.
  143. Hattinger C.M., Patrizio M.P., Tavanti E., Luppi S., Magagnoli F., Picci P., Serra M. Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments? Expert Rev Mol Diagn 18(11):947-961, 2018.
  144. Koster R., Panagiotou O.A., Wheeler W.A., Karlins E., Gastier-Foster J.M., Caminada de Toledo S.R., Petrilli A.S., Flanagan A.M., Tirabosco R., Andrulis I.L., Wunder J.S., Gokgoz N., Patino-Garcia A., Lecanda F., Serra M., Hattinger C., Picci P., Scotlandi K., Thomas D.M., Ballinger M.L., Gorlick R., Barkauskas D.A., Spector L.G., Tucker M., Belynda D.H., Yeager M., Hoover R.N., Wacholder S., Chanock S.J., Savage S.A., Mirabello L. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer 142(8):1594-1601, 2018.
  145. Marques da Costa M.E., Daudigeos-Dubus E., Gomez-Brouchet A., Bawa O., Rouffiac V., Serra M., Scotlandi K., Santos C., Geoerger B., Gaspar N. Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice. Cancer Med 7(3):665-676, 2018.
  146. Martella E, Ferroni C, Guerrini A, Ballestri M, Columbaro M, Santi S, Sotgiu G, Serra M, Donati DM, Lucarelli E, Varchi G, Duchi S. Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma. Int J Mol Sci 19(11), 2018. pii: E3670. doi: 10.3390/ijms19113670.

(Last update: December 2018)

Utilizza SharethisShareThis  Scrivi una email  Vai a facebook  Vai a twitter